


Patent claims

1. A solid preparation, comprising
component 1) 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide,
5 component 2) the compound of formula I

10



(I)

15

and/or a stereoisomeric form of the compound of the formula I
and/or a physiologically tolerated salt of the compound of the
formula I, and

20

3) a pharmaceutically tolerated excipient,
wherein the content of component 1 is from 2 to 20 mg and the
content of component 2) is from 0.3% to 50% of that of component
1).

25

2. The preparation as claimed in claim 1, wherein the content of
component 2) is from 0.5% to 20% of that of component 1).

30

3. The preparation as claimed in claims 1 or 2, wherein the content of
component 2) is from 0.8 to 15% of that of component 1).

35

4. The preparation as claimed in one or more of claims 1 to 3, wherein
the content of component 2) is from 1% to 10% of that of
component 1.

5. The preparation as claimed in one or more of claims 1 to 4, wherein
the content of component 2) is from 1% to 5% of that of component
1.

6. The preparation as claimed in one or more of claims 1 to 5, which comprises components 1 and 2 in an administration form for rectal or oral administration.

5 7. The preparation as claimed in one or more of claims 1 to 6, wherein components 1 and 2 are present in similar, separate administration forms for being administered at the same time.

10 8. The preparation as claimed in one or more of claims 1 to 7, wherein components 1 and 2 are present in separate, different administration forms for being administered at the same time.

15 9. The use of the preparation as claimed in one or more of claims 1 to 8 for treating immunological diseases.

20 10. The use of the preparation as claimed in one or more of claims 1 to 8 for treating acute immunological events, such as sepsis, allergy and graft-versus-host reactions or host-versus-graft reactions, or autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis, or psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis or hepatic fibrosis, or cancerous diseases, such as lung cancer, leukemia, ovarian cancer, sarcoma, Kaposi's sarcoma, meningioma, intestinal cancer, lymph node cancer, brain tumours, breast cancer, pancreatic cancer, prostate cancer or skin cancer.

25 11. A process for producing the preparation as claimed in one or more of claims 1 to 8, which comprises processing 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide, the compound of the formula I and/or a physiologically tolerated salt of the compound of the formula I and/or a stereoisomeric form of the compound of formula I and a pharmaceutical excipient into a pharmaceutical administration form.

ABAI